Alvotech and Advanz Pharma Announce Positive CHMP Opinion for AVT06 Biosimilar to Eylea®

Alvotech and Advanz Pharma announced a positive opinion from the European Medicines Agency’s CHMP for AVT06, a proposed biosimilar to Eylea® (aflibercept 2 mg), clearing a path for its potential marketing authorization in the European Economic Area. This development is significant as AVT06 targets various prevalent eye disorders, including neovascular AMD, and aims to address a substantial market, given Eylea®'s global sales of approximately $9 billion in 2024, with one-third attributed to Europe. The approval would enhance patient access to a critical treatment while opening a lucrative market opportunity for the companies.

Analysis

Alvotech (ALVO) has achieved a significant regulatory milestone with the positive opinion from the European Medicines Agency's CHMP for its aflibercept biosimilar, AVT06. This recommendation substantially de-risks the path to marketing authorization within the European Economic Area, positioning Alvotech and its partner Advanz Pharma to compete for a share of the European Eylea market, which constituted approximately one-third of the drug's US$9 billion global sales in 2024. The CHMP's decision is supported by positive top-line data from a January 2024 confirmatory study that demonstrated therapeutic equivalence to the reference product, Eylea®. This development poses a direct competitive threat to Regeneron (REGN), the originator of Eylea®. Institutional investor sentiment appears divided, however, with recent filings showing significant new positions by firms like T. Rowe Price and Vanguard, but also substantial reductions or exits by others such as Sculptor Capital and Morgan Stanley. This divergence suggests differing views on the company's execution risk and valuation, despite the positive regulatory news. While the CHMP opinion is a major catalyst, uncertainty remains regarding the exact timing of final European Commission approval and the subsequent commercial launch.

Key Decisions for Investors

• The positive CHMP opinion serves as a major de-risking event, and investors with a bullish outlook on the biosimilar market could view this as a key catalyst for Alvotech's European revenue potential.
• Monitor for forthcoming announcements on the final European Commission decision and specific launch timelines, as these are the next critical inflection points for valuing the commercial opportunity of AVT06.
• Note the divided institutional sentiment, with significant buying and selling from major funds, which warrants a careful assessment of risk tolerance regarding execution and competitive pressures.
• For investors holding or monitoring Regeneron (REGN), this development signals impending revenue and market share pressure for its Eylea franchise in the lucrative European market.